However, in cutaneous leishmaniasis, anti-PD-L1 treatment, but not anti-PD-L2, significantly increased IFN-γ-producing CD4+ and CD8+ T cells, with significantly lower parasite loads but bigger lesions [34]. Here, PDCD1LG2 is linked to cutaneous leishmaniasis.